The Relationship Between PDE-5 Inhibitors and NAION

Update Item Information
Identifier 20150223_nanos_journalclub1_02
Title The Relationship Between PDE-5 Inhibitors and NAION
Creator Howard D. Pomeranz, MD
Subject Erectile Dysfunction Drug; Non-Arteritic Anterior Ischemic Optic Neuropathy; Phosphodiesterase 5 (PDE-5) Inhibitor; Pfizer; Sildenafil
History Sildenafil was first synthesized by pharmaceutical chemists working at Pfizer. It was initially studied for use in hypertension and angina. Phase I clinical trials suggested that the drug had little effect on angina but could induce penile erection. Sildenafil (Viagra®) was patented in 1996 and approved by the FDA for use in erectile dysfunction (ED) in March, 1998. Vardenafil (Levitra®) was approved by the FDA for treatment of erectile dysfunction in August, 2003 and tadalafil (Cialis®) in November, 2003. Avanafil (Stendra®) was approved in April, 2012. Udenafil (Zydena) is not FDA approved for sale in the United States, but is available in Korea, Russia and the Philippines.
Date 2015
Language eng
Format application/pdf
Type Text
Relation is Part of NANOS Annual Meeting Journal Club, 2015
Collection Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Rights Management Copyright 2015. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6613wxq
Contributor Primary Howard D. Pomeranz
Setname ehsl_novel_fbw
ID 179289
Reference URL https://collections.lib.utah.edu/ark:/87278/s6613wxq